DCB-USA LLC and the Development Center for Biotechnology have patented heterocycle compounds acting as fMet-Leu-Phe receptor (fMLP; FPR1) antagonists reported to be useful for the treatment of cancer, acute respiratory distress syndrome, asthma, arthritis, chronic obstructive pulmonary disease, lung injury, ischemia-reperfusion injury and septicemia.